No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
50 – 90
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
10 (estimated)
Sponsor
Emory University · Other
Who this trial is looking for
This trial is looking for older adults with Mild Cognitive Impairment or Alzheimer's Disease to understand how these conditions affect walking. Participants will undergo assessments and may participate in exercise based interventions.
Are You a Good Fit for This Trial?
Must not be takingAntipsychoticsOpioidsStimulantsChemotherapyLevodopa
Rules you outPsychotic disordersSubstance Use DisorderMajor Depressive DisorderGeneralized Anxiety Disorder
You may be able to join if
I have been diagnosed with Mild Cognitive Impairment or Alzheimer's Disease.
I can walk 10 or more feet without an assistive device.
I have completed six grades of education or have a good work history.
I have a Mini-Mental State Exam score between 20 and 26.
I have a Clinical Dementia Rating score of 0.5.
I have evidence of impaired executive function based on the Montreal Cognitive Assessment.
I have not been hospitalized in the last 60 days.
You may not be able to join if
I have had an acute medical illness requiring hospitalization.
I have uncontrolled congestive heart failure.
I have a history of stroke.
I cannot perform study procedures.
I have severe arthritis or mobility problems.
I take medications that could negatively affect my cognition.
I have a psychotic disorder.
I have Major Depressive Disorder or Generalized Anxiety Disorder within the last six months.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
In people with Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD), reduced capacity for locomotor adaptation is a fundamental but poorly understood mechanism that can be a sensitive biomarker of cognitive-motor impairments. It is also an important therapeutic target for exercise-based interventions to improve walking function. The overall goal of this study is to understand the effects o…
In people with Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD), reduced capacity for locomotor adaptation is a fundamental but poorly understood mechanism that can be a sensitive biomarker of cognitive-motor impairments. It is also an important therapeutic target for exercise-based interventions to improve walking function. The overall goal of this study is to understand the effects of MCI and AD on locomotor adaptation and walking function.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* AD and MCI will be defined through formal diagnosis provided by a board-certified Neurologist. Amnestic MCI will be defined using the AD Neuroimaging Initiative (ADNI) criteria. All MCI participants in ADNI are required to have an amnestic subtype defined as:
* Subjective m…
Inclusion Criteria:
* AD and MCI will be defined through formal diagnosis provided by a board-certified Neurologist. Amnestic MCI will be defined using the AD Neuroimaging Initiative (ADNI) criteria. All MCI participants in ADNI are required to have an amnestic subtype defined as:
* Subjective memory concern or a memory problem noted by their partner
* Abnormal memory function documented by a specified education adjusted cutoff score on the delayed paragraph recall of the Anna Thompson story of the Logical Memory subtest from the Wechsler Memory Scale-Revised
* Mini-Mental State Exam (MMSE) score between 20 and 26 (inclusive). Exceptions may be made for subjects with less than 8 years of education at the discretion of the PI. (iv) Single or multi-domain amnestic MCI (both subtypes are at high risk for progression to AD)
* Clinical Dementia Rating (CDR) = 0.5 (Memory Box score must be at least 0.5)
* General functional performance sufficiently preserved
* Evidence of impaired executive function based on Montreal Cognitive Assessment (MoCA) score 13-17
* Able to walk 10 or more feet without an assistive device
* Completed six grades of education or has a good work history (sufficient to exclude intellectual disabilities)
* Not hospitalized within the last 60 days
Exclusion Criteria:
* Acute medical illness requiring hospitalization
* Uncontrolled congestive heart failure
* History of stroke
* Inability to perform study procedures
* Medical or physical conditions that would preclude participation or walking (e.g., severe arthritis or mobility problems, uncontrolled hypertension or diabetes, renal failure, history of angina with activity)
* On medications that could adversely affect cognition, eg: antipsychotics, opioids, stimulants, chemotherapy, anti-parkinsonian drugs (eg Levodopa), neurologic prescriptions to treat Multiple sclerosis and/or Parkinson's
* Psychotic disorders
* Confounding neurologic conditions (e.g., active central nervous system (CNS) opportunistic infections, seizure disorders, head injury with loss of consciousness \>30 minutes, intracranial neoplasms, stroke with neurological or neuropsychiatric sequelae)
* Substance Use Disorder, Major Depressive and Generalized Anxiety Disorders within six months of evaluation
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.